Cancer Treatment Gets Cheaper: NPPA Slashes Trade Margins for 137 Drugs
NPPA caps trade margins for 137 anti-cancer drugs, potentially slashing MRPs by up to 70% to make cancer treatment more affordable in India.
In a major move to make life-saving treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has implemented a Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs price cap. This intervention, carried out under the Department of Pharmaceuticals within the Ministry of Chemicals and Fertilizers, aims to curb excessive profit margins in the distribution chain and ensure that patients have better access to essential medicines.
Massive Price Drop Expected
The impact of this decision is expected to be substantial. Depending on the existing price structures of the medicines, the Maximum Retail Price (MRP) of these identified non-scheduled anti-cancer drugs could drop by as much as 70%. This is intended to provide significant financial relief to families battling the high costs associated with cancer therapy.
Building on Previous Success
This is not the first time the NPPA has taken such a step. The current move expands upon a 2019 pilot TMR exercise. During that initial phase, trade margins for 42 anti-cancer drugs were capped at 30%, which resulted in a price reduction of up to 90% for 526 different brands of non-scheduled anti-cancer medicines.
How the Drugs Were Selected
The list of 137 drugs was not chosen randomly. It was recommended by an Expert Committee under the Directorate General of Health Services (DGHS). This committee consisted of:
- Leading oncologists
- Medical specialists
- Experts from various hospitals across India
- Government officials
The government has indicated that this list will be updated periodically to ensure the most critical medicines remain affordable.
The New Rules: 30% Margin Cap
Following the guidelines of Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, the NPPA has capped the trade margin at 30% of the MRP. This measure is designed to balance the needs of the patient with the sustainability of the industry, safeguarding legitimate manufacturer revenues while preventing artificial shortages in the market.
Timeline and Compliance
The revised pricing structure will officially come into effect on November 9. To ensure a smooth transition, the government has laid out strict requirements:
- Manufacturers: Must inform the NPPA of their revised prices within seven days of the Gazette notification. They are also required to publish these price lists on their websites and share them with all hospitals and retailers.
- Retailers and Hospitals: Must charge the reduced prices starting November 9 and display the revised rates prominently in their pharmacies and on their websites.
- Supply Chain: Since many anti-cancer drugs are supplied directly to medical institutions, hospitals bear the responsibility of ensuring the revised prices are implemented.
Monitoring and Consumer Empowerment
To prevent malpractice and ensure compliance, State Drug Controllers have been tasked with monitoring manufacturers, dealers, retailers, and hospitals. Pharmaceutical companies are further mandated to maintain their current production and supply levels to avoid any interruption in patient care.
For patients and caregivers, the government has provided tools to verify the costs. Consumers can check the revised prices of these drugs using the Pharma Sahi Daam app or by visiting the official NPPA website.